Literature DB >> 16302615

Risk factors for postoperative ischemic complications in patients with moyamoya disease.

Se-Hyuk Kim1, Joong-Uhn Choi, Kook-Hee Yang, Tae-Gon Kim, Dong-Seok Kim.   

Abstract

OBJECT: The aim of this study was to determine the risk factors associated with the development of postoperative ischemic complications after surgical revascularization used to treat pediatric patients with ischemic moyamoya disease.
METHODS: The clinical, imaging, and perioperative data from 170 procedures in 90 children who underwent indirect revascularization surgery were retrospectively reviewed. To clarify the risk factors, cases with identified ischemic complications and those without such events were compared. For this study, a postoperative ischemic complication was defined as a newly developed infarction within 2 weeks after surgery, which was confirmed by follow-up imaging studies.
CONCLUSIONS: The higher ischemic risks from surgical treatment should be considered for patients with moyamoya disease who are younger than 3 years of age and have a preoperative cerebral infarction. It is also recommended that the revascularization surgery be delayed for at least 6 weeks after the development of the previous cerebral infarction.

Entities:  

Mesh:

Year:  2005        PMID: 16302615     DOI: 10.3171/ped.2005.103.5.0433

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  The promotion of pediatric neurosurgery throughout the world.

Authors:  Joong-Uhn Choi
Journal:  Childs Nerv Syst       Date:  2007-09       Impact factor: 1.475

2.  Moyamoya disease, revascularisation surgery and anaesthetic considerations.

Authors:  Yashar Ilkhchoui; Pramod V Panikkath; Hugh Martin
Journal:  BMJ Case Rep       Date:  2014-01-08

3.  Postoperative stroke and neurological outcomes in the early phase after revascularization surgeries for moyamoya disease: an age-stratified comparative analysis.

Authors:  Yoshio Araki; Kinya Yokoyama; Kenji Uda; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Masahiro Nishihori; Takashi Izumi; Masaki Sumitomo; Sho Okamoto; Kota Matsui; Ryo Emoto; Toshihiko Wakabayashi; Shigeyuki Matsui; Atsushi Natsume
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

4.  High variance of intraoperative blood pressure predicts early cerebral infarction after revascularization surgery in patients with Moyamoya disease.

Authors:  Jiaxi Li; Yahui Zhao; Meng Zhao; Penghui Cao; Xingju Liu; Hao Ren; Dong Zhang; Yan Zhang; Rong Wang; Jizong Zhao
Journal:  Neurosurg Rev       Date:  2019-06-15       Impact factor: 3.042

5.  Unpredictable postoperative global cerebral infarction in the patient of williams syndrome accompanying moyamoya disease.

Authors:  Yang-Won Sim; Mou-Seop Lee; Young-Gyu Kim; Dong-Ho Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

Review 6.  The prospects and pitfalls in the endovascular treatment of moyamoya disease-associated intracranial aneurysms.

Authors:  Kun Hou; Guichen Li; Tengfei Luan; Kan Xu; Jinlu Yu
Journal:  Neurosurg Rev       Date:  2020-02-12       Impact factor: 3.042

7.  Ischemic complications occurring in the contralateral hemisphere after surgical treatment of adults with moyamoya disease.

Authors:  Young Jin Jung; Jae Sung Ahn; Do Hoon Kwon; Byung Duk Kwun
Journal:  J Korean Neurosurg Soc       Date:  2011-12-31

8.  Angiographic results of indirect and combined bypass surgery for adult moyamoya disease.

Authors:  In Jae Choi; Sung Jin Cho; Jae Chil Chang; Sukh Que Park; Hyung Ki Park
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2012-09-28

Review 9.  Cognitive Outcome of Pediatric Moyamoya Disease.

Authors:  Kyu-Won Shim; Eun-Kyung Park; Ju-Seong Kim; Dong-Seok Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

10.  Risk factors for postoperative ischemic complications in pediatric moyamoya disease.

Authors:  Xiaofeng Deng; Peicong Ge; Rong Wang; Dong Zhang; Jizong Zhao; Yan Zhang
Journal:  BMC Neurol       Date:  2021-06-22       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.